$AURX
Nuo Therapeutics Inc Stock $aurx

$aurx Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000114420414031238 Filed on May 15, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$1.846M	$2.317M
YoY Change	-20.34%	-23.19%
Cost Of Revenue	$1.453M	$1.272M
YoY Change	14.19%	49.98%
Gross Profit	$392.9K	$1.045M
YoY Change	-62.4%	-51.81%
Gross Profit Margin	21.28%	45.09%
Selling, General & Admin	$3.609M	$5.090M
YoY Change	-29.09%	28.54%
% of Gross Profit	918.75%	487.15%
Research & Development	$1.434M	$901.7K
YoY Change	58.99%	152.36%
% of Gross Profit	364.91%	86.3%
Depreciation & Amortization	$217.7K	$332.9K
YoY Change	-34.62%	48.19%
% of Gross Profit	55.41%	31.87%
Operating Expenses	$5.043M	$6.048M
YoY Change	-16.62%	23.74%
Operating Profit	-$4.650M	-$5.003M
YoY Change	-7.06%	83.98%
Interest Expense	-$1.179M	-$519.0K
YoY Change	127.19%	94.29%
% of Operating Profit
Other Income/Expense, Net	-$978.1K	-$330.5K
YoY Change	195.98%	-83.47%
Pretax Income	-$5.628M	-$5.334M
YoY Change	5.52%	13.02%
Income Tax	$4.645K	$4.890K
% Of Pretax Income
Net Earnings	-$5.633M	-$5.339M
YoY Change	5.51%	13.02%
Net Earnings / Revenue	-305.15%	-230.38%
Basic Earnings Per Share	-$0.05	-$0.05
Diluted Earnings Per Share	-$0.05	-$0.05
COMMON SHARES
Basic Shares Outstanding	111.2M shares	99.11M shares
Diluted Shares Outstanding	111.2M shares

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.650M	$7.220M
YoY Change	5.96%	-14.86%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$2.470M	$2.210M
YoY Change	11.76%	225.0%
Inventory	$731.5K	$930.0K
Prepaid Expenses
Receivables	$2.370M	$1.260M
Other Receivables	$0.00	$1.110M
Total Short-Term Assets	$13.22M	$12.73M
YoY Change	3.87%	10.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$870.0K	$2.210M
YoY Change	-60.63%	22.93%
Goodwill	$1.129M
YoY Change
Intangibles	$33.68M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.340M	$670.0K
YoY Change	100.0%	7138.55%
Total Long-Term Assets	$37.02M	$38.05M
YoY Change	-2.71%	0.6%
TOTAL ASSETS
Total Short-Term Assets	$13.22M	$12.73M
Total Long-Term Assets	$37.02M	$38.05M
Total Assets	$50.24M	$50.78M
YoY Change	-1.06%	2.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.940M	$2.340M
YoY Change	239.32%	34.48%
Accrued Expenses		$900.0K
YoY Change		50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$8.411M	$3.490M
YoY Change	140.99%	-21.12%
LONG-TERM LIABILITIES
Long-Term Debt	$2.180M	$6.230M
YoY Change	-65.01%	196.67%
Other Long-Term Liabilities	$14.05M	$710.0K
YoY Change	1878.87%	-96.25%
Total Long-Term Liabilities	$16.23M	$6.940M
YoY Change	133.86%	-63.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.411M	$3.490M
Total Long-Term Liabilities	$16.23M	$6.940M
Total Liabilities	$24.71M	$10.48M
YoY Change	135.77%	-73.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$96.86M
YoY Change
Common Stock	$12.04K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.03M	$40.30M
YoY Change
Total Liabilities & Shareholders Equity	$50.24M	$50.78M
YoY Change	-1.06%	2.9%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$5.633M	-$5.339M
YoY Change	5.51%	13.02%
Depreciation, Depletion And Amortization	$217.7K	$332.9K
YoY Change	-34.62%	48.19%
Cash From Operating Activities	-$3.910M	-$4.210M
YoY Change	-7.13%	727.87%
INVESTING ACTIVITIES
Capital Expenditures	$75.73K	-$100.0K
YoY Change	-175.73%	-136.26%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$80.00K
YoY Change	-100.0%	-38.46%
Cash From Investing Activities	-$80.00K	-$20.00K
YoY Change	300.0%	-86.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.666M	$4.852M
YoY Change	-24.43%	-19.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.350M	8.830M
YoY Change	-5.44%	28.16%
NET CHANGE
Cash From Operating Activities	-3.910M	-4.210M
Cash From Investing Activities	-80.00K	-20.00K
Cash From Financing Activities	8.350M	8.830M
Net Change In Cash	4.360M	4.600M
YoY Change	-5.22%	-26.22%
FREE CASH FLOW
Cash From Operating Activities	-$3.910M	-$4.210M
Capital Expenditures	$75.73K	-$100.0K
Free Cash Flow	-$3.986M	-$4.110M
YoY Change	-3.02%	424.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33677371	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	12042	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17206	USD
CY2012Q4	us-gaap	Cash Cash	2615805	USD
CY2014Q1	cmxi	Research And Development ResearchAndDevelopment	374000	USD
CY2009Q3	cmxi	Letter Of Credit LetterOfCredit	50000	USD
CY2014Q1	cmxi	Business Acquisitions Contingent Consideration Shares Issuable BusinessAcquisitionsContingentConsiderationSharesIssuable	20309723	shares
CY2013Q1	cmxi	Operating Expense Recognized Value OperatingExpenseRecognizedValue	1006000	USD
CY2014Q1	us-gaap	Cash Cash	7653566	USD
CY2013Q4	us-gaap	Cash Cash	3286713	USD
CY2014Q1	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	53356	USD
CY2013Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	53257	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2371189	USD
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3926681	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	731533	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	1111507	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1979463	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1258282	USD
CY2014Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	433314	USD
CY2013Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	316551	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	13222421	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	9952991	USD
CY2014Q1	cmxi	Property Plant And Equipments Net PropertyPlantAndEquipmentsNet	869112	USD
CY2013Q4	cmxi	Property Plant And Equipments Net PropertyPlantAndEquipmentsNet	919469	USD
CY2014Q1	us-gaap	Deferred Costs DeferredCosts	1342976	USD
CY2013Q4	us-gaap	Deferred Costs DeferredCosts	482349	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33768954	USD
CY2014Q1	us-gaap	Goodwill Goodwill	1128517	USD
CY2013Q4	us-gaap	Goodwill Goodwill	1128517	USD
CY2014Q1	us-gaap	Assets Assets	50240397	USD
CY2013Q4	us-gaap	Assets Assets	46252280	USD
CY2014Q1	us-gaap	Liabilities Liabilities	24708473	USD
CY2013Q4	us-gaap	Liabilities Liabilities	19440286	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Temporary Equity Redemption Value TemporaryEquityRedemptionValue	500000	USD
CY2013Q4	us-gaap	Temporary Equity Redemption Value TemporaryEquityRedemptionValue	500000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	10626	USD
CY2014Q1	cmxi	Common Stock Issuable CommonStockIssuable	432100	USD
CY2013Q4	cmxi	Common Stock Issuable CommonStockIssuable	432100	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121449271	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	117097844	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96861489	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91228576	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	25031924	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	26311994	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50240397	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46252280	USD
CY2014Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	909091	shares
CY2014Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	909091	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121326733	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107164855	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121326733	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107164855	shares
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Use of Estimates</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, valuation of derivative liabilities and contingent consideration, contingent liabilities, fair value of long-lived assets, deferred taxes and associated valuation allowance, and the depreciable lives of fixed assets. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Credit Concentration</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Approximately 83% of our accounts receivable balance at March 31, 2014 was from Arthrex, related to sales of Angel.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We use single suppliers for several components of the Angel and AutoloGel product lines. We outsource the manufacturing of various products, including component parts for Angel, to contract manufacturers. While we believe these manufacturers to be of sufficient competency, quality, reliability, and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of AutoloGel are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	2253129	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1423218	USD
CY2013Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	100594	USD
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	64172	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	322117	USD
CY2013Q1	us-gaap	Revenues Revenues	2317301	USD
CY2014Q1	us-gaap	Revenues Revenues	1845929	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1408821	USD
CY2013Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	5134	USD
CY2014Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	44244	USD
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	1272444	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	1044857	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	392864	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	6048067	USD
CY2014Q1	cmxi	Salaries And Compensation SalariesAndCompensation	1682086	USD
CY2013Q1	cmxi	Consulting Fees ConsultingFees	533512	USD
CY2014Q1	cmxi	Consulting Fees ConsultingFees	836332	USD
CY2013Q1	cmxi	Salaries And Compensation SalariesAndCompensation	1998196	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	5043024	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5003210	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4650160	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-519029	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1179170	USD
CY2013Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	193093	USD
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	201062	USD
CY2013Q1	us-gaap	Professional Fees ProfessionalFees	125348	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4533	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-330469	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-978108	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5333679	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5628268	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4890	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4645	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-5338569	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5632913	USD
CY2014Q1	us-gaap	Professional Fees ProfessionalFees	239092	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	901685	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	953683	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2489326	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1331831	USD
CY2014Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2993860	USD
CY2013Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1515540	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9441917	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1733055	USD
CY2014Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	12435777	USD
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3248595	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	11249023	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1860779	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-201062	USD
CY2014Q1	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	53000	USD
CY2014Q1	cmxi	Time Deposits Annual Interest Rate TimeDepositsAnnualInterestRate	0.0010	pure
CY2014Q1	cmxi	Time Deposits Maturity Date TimeDepositsMaturityDate	2014-10-24
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	9629	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	13433	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	332947	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217673	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	169263	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	178000	USD
CY2013Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	42753	USD
CY2014Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	194846	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-33952	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73634	USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4890	USD
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4645	USD
CY2013Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-7837	USD
CY2014Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013Q1	cmxi	Amendment To Contingent Consideration Effect On Income AmendmentToContingentConsiderationEffectOnIncome	1006159	USD
CY2014Q1	cmxi	Amendment To Contingent Consideration Effect On Income AmendmentToContingentConsiderationEffectOnIncome	0	USD
CY2013Q1	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-19867	USD
CY2014Q1	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-381201	USD
CY2013Q1	cmxi	Issuance Of Warrants Effect On Income IssuanceOfWarrantsEffectOnIncome	303517	USD
CY2014Q1	cmxi	Issuance Of Warrants Effect On Income IssuanceOfWarrantsEffectOnIncome	0	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	642062	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1542059	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-235852	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-379974	USD
CY2013Q1	us-gaap	Cash Cash	7216081	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	8788168	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4851738	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3666260	USD
CY2013Q1	cmxi	Repayment Of Note Payable RepaymentOfNotePayable	270000	USD
CY2014Q1	cmxi	Repayment Of Note Payable RepaymentOfNotePayable	4101143	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1280629	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1189046	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	366300	USD
CY2013Q1	cmxi	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	809648	USD
CY2014Q1	cmxi	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	721280	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	677807	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-78132	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-371575	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6782	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	108798	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4213585	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3910699	USD
CY2013Q1	cmxi	Payments To Acquire Property Plant And Equipments PaymentsToAcquirePropertyPlantAndEquipments	100000	USD
CY2014Q1	cmxi	Payments To Acquire Property Plant And Equipments PaymentsToAcquirePropertyPlantAndEquipments	75733	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	82794	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-75733	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4249329	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8831067	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8353285	USD
CY2013Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	4600276	USD
CY2014Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	4366853	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	366300	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	366300	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	300000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	277800	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	2140900	USD
CY2014Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	274750	USD
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	12435777	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3248595	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	193876	USD
CY2013Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	185405	USD
CY2014Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	73234	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	68589	USD
CY2014Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	48527	USD
CY2013Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	44194	USD
CY2014Q1	cmxi	Conditional Grant Payable ConditionalGrantPayable	30000	USD
CY2013Q4	cmxi	Conditional Grant Payable ConditionalGrantPayable	30000	USD
CY2014Q1	cmxi	Term Loan Fee Payable Noncurrent TermLoanFeePayableNoncurrent	0	USD
CY2013Q4	cmxi	Term Loan Fee Payable Noncurrent TermLoanFeePayableNoncurrent	38738	USD
CY2014Q1	cmxi	Derivative Liabilities And Other Liabilities Noncurrent DerivativeLiabilitiesAndOtherLiabilitiesNoncurrent	12781414	USD
CY2013Q4	cmxi	Derivative Liabilities And Other Liabilities Noncurrent DerivativeLiabilitiesAndOtherLiabilitiesNoncurrent	3615521	USD
CY2013Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.1	pure
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1300000	USD
CY2013Q1	cmxi	Class Of Warrant Or Rights Issued To Lender ClassOfWarrantOrRightsIssuedToLender	152000	USD
CY2013Q1	cmxi	Class Of Warrant Or Rights Issued To Guarantors ClassOfWarrantOrRightsIssuedToGuarantors	304000	USD
CY2013Q4	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	750000	USD
CY2014Q1	cmxi	Stock Issued During Period Shares Issued In Registered Private Offering StockIssuedDuringPeriodSharesIssuedInRegisteredPrivateOffering	3846154	shares
CY2014Q1	cmxi	Stock Issued During Period For Equity Purchase Agreement One StockIssuedDuringPeriodForEquityPurchaseAgreementOne	3750000	shares
CY2014Q1	cmxi	Stock Issued During Period For Fees Of Equity Purchase Agreement StockIssuedDuringPeriodForFeesOfEquityPurchaseAgreement	43865	shares
CY2014Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	540000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	14161878	shares
CY2014Q1	cmxi	Proceeds From Issuance Of Shares In Registered Private Offering ProceedsFromIssuanceOfSharesInRegisteredPrivateOffering	1911695	USD
CY2014Q1	cmxi	Proceeds From Issuance Of Shares On Equity Purchase Agreement One ProceedsFromIssuanceOfSharesOnEquityPurchaseAgreementOne	1754565	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3666260	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	222500	shares
CY2013Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5000000	USD
CY2013Q1	us-gaap	Share Price SharePrice	0.55
CY2013Q1	cmxi	Warrants Exercise Price WarrantsExercisePrice	0.75
CY2013Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6363638	shares
CY2013Q1	cmxi	Stock Issued During Period Shares Investors StockIssuedDuringPeriodSharesInvestors	9090911	shares
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.52
CY2014Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2936423	USD
CY2014Q1	cmxi	Noncash Or Part Noncash Acquisition Effect Of Modification Of Convertible Debt NoncashOrPartNoncashAcquisitionEffectOfModificationOfConvertibleDebt	2860627	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7681188	USD
CY2014Q1	cmxi	Derivative Liability For Embedded Conversion Option DerivativeLiabilityForEmbeddedConversionOption	3567835	USD
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99105448	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111222841	shares
CY2014Q1	cmxi	Share Proceeds From Issuance Of Private Placement ShareProceedsFromIssuanceOfPrivatePlacement	2000000	USD
CY2014Q1	cmxi	Stock Issuance From Private Placement StockIssuanceFromPrivatePlacement	3846154	shares
CY2014Q1	cmxi	Warrants Outstanding Options For Commonstock WarrantsOutstandingOptionsForCommonstock	2884615	shares
CY2014Q1	cmxi	Warrants Options Issue Price WarrantsOptionsIssuePrice	0.52
CY2014Q1	cmxi	Fair Value Of Warrants FairValueOfWarrants	1100000	USD
CY2014Q1	cmxi	Warrants And Fees WarrantsAndFees	136000	USD
CY2014Q1	cmxi	Debt Conversion Converted Instrument Shares Issued One DebtConversionConvertedInstrumentSharesIssuedOne	5981859	shares
CY2013Q1	cmxi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeRate	0.0085	pure
CY2014Q1	cmxi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeRate	0.0158	pure
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.34	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.26	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2013Q4	cmxi	Warrants Outstanding Issue One WarrantsOutstandingIssueOne	23019301	shares
CY2014Q1	cmxi	Debt Instrument Warrants Issued For Convertible Bridge Notes DebtInstrumentWarrantsIssuedForConvertibleBridgeNotes	232964	shares
CY2014Q1	cmxi	Debt Instrument Warrants Issued For Equity Placement DebtInstrumentWarrantsIssuedForEquityPlacement	2884615	shares
CY2014Q1	cmxi	Debt Instrument Warrants Issued For Convertible Notes DebtInstrumentWarrantsIssuedForConvertibleNotes	25115384	shares
CY2014Q1	cmxi	Debt Instrument Warrants Issued Fortrust Notes DebtInstrumentWarrantsIssuedFortrustNotes	750000	shares
CY2014Q1	cmxi	Debt Instrument Warrants Issued For Convertible Notes One DebtInstrumentWarrantsIssuedForConvertibleNotesOne	1474615	shares
CY2014Q1	cmxi	Warrants Expired WarrantsExpired	200000	shares
CY2014Q1	cmxi	Warrants Outstanding Issue One WarrantsOutstandingIssueOne	53276879	shares
CY2014Q1	cmxi	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Exercise Price Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePricePerShare	0.61
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	331065	shares
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7940540	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8018672	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	470009	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	740990	USD
CY2014Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1800000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8410549	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	16000	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27245975	shares
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10559662	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2100000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3620593	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h2 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Note 1  Business and Presentation</h2> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Description of Business</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Cytomedix, Inc. (“Cytomedix,” the “Company,” “we,” “us,” or “our”) is a regenerative therapies company marketing products within the U.S. and internationally. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous from self-biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth drivers in the U.S. include Medicare coverage for the treatment of chronic wounds under a National Coverage Determination when registry data is collected under Coverage with Evidence Development (“CED”), and a worldwide distribution and licensing agreement that allows our partner to promote the Angel System for all uses other than wound care.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Our current commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. We currently have two distinct platelet rich plasma (“PRP”) devices, the AutoloGel<sup>TM</sup> System for wound care and the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Our sales are predominantly in the United States, where we sell our products through direct sales representatives and distributors. Since August 8, 2013, Arthrex, Inc. (“Arthrex”), as our exclusive distributor for Angel, accounted for 100% of our Angel sales.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, licensing arrangements, royalties, and product revenues. We have incurred, and continue to incur, recurring losses and negative cash flows. On March 31, 2014, we entered into a $35,000,000 convertible debt facility, of which $9,000,000 was funded on March 31, 2014 and the remaining $26,000,000 will be funded upon the authorization of our shareholders to increase the Company’s authorized capital stock (Notes 2 and 6). In addition, on March 31, 2014 we raised $2.0 million of gross proceeds from the sale of our common stock and warrants to an accredited investor (Notes 2 and 7). We used approximately $3.8 million of the net proceeds from these transactions to retire an outstanding term loan, approximately $0.35 million to repay a portion of previously outstanding convertible debt, and we converted approximately $2.6 million previously outstanding convertible debt into common stock (Notes 2 and 6).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">At March 31, 2014, we had approximately $7.7 million of cash on hand. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe that our current resources, including the anticipated funding of the remaining portion of the convertible debt facility, will be sufficient to fund our operations through at least March 31, 2015. Accordingly, management believes the going-concern basis is appropriate for the accompanying consolidated financial statements.</div> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2013, has been derived from audited financial statements of that date. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our annual report on Form 10-K for the year ended December 31, 2013. Certain prior period information has been reclassified to conform to the current period presentation.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Principles of Consolidation</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary. All significant inter-company accounts and transactions are eliminated in consolidation.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, valuation of derivative liabilities and contingent consideration, contingent liabilities, fair value of long-lived assets, deferred taxes and associated valuation allowance, and the depreciable lives of fixed assets. Actual results could differ from those estimates.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Credit Concentration</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Approximately 83% of our accounts receivable balance at March 31, 2014 was from Arthrex, related to sales of Angel.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We use single suppliers for several components of the Angel and AutoloGel product lines. We outsource the manufacturing of various products, including component parts for Angel, to contract manufacturers. While we believe these manufacturers to be of sufficient competency, quality, reliability, and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of AutoloGel are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash Equivalents</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts Receivable</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We generate accounts receivable from the sale of our products. We provide for a reserve against receivables for estimated losses that may result from a customer’s inability or unwillingness to pay. The allowance for doubtful accounts is estimated primarily based upon historical write-off percentages, known problem accounts, and current economic conditions. Accounts are written off against the allowance for doubtful accounts when we determine that amounts are not collectable. Recoveries of previously written-off accounts are recorded when collected. At March 31, 2014 and December 31, 2013, we maintained an allowance for doubtful accounts of $30,000 and $16,000, respectively.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Our inventory is produced by third party manufacturers and consists primarily of finished goods. Inventory cost is determined on a first-in, first-out basis and is stated at the lower of cost or net realizable value. Our primary product is the Angel Processing set which has a shelf life of three years. We also maintain an inventory of kits, reagents, and other disposables that have shelf lives that generally range from ten months to five years. Expired products are segregated and used for demonstration purposes only; we write off expired inventory through cost of sales.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from three to five years for all assets except for furniture, lab, and manufacturing equipment which is depreciated over seven and ten years, respectively. Leasehold improvements are stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over the lesser of the expected lease term or its estimated useful life ranging from three to six years. Amortization of leasehold improvements is included in depreciation expense. Maintenance and repairs are charged to operations as incurred. When assets are disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income (expense).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Centrifuges may be sold, leased, or placed at no charge with customers. Depreciation expense for centrifuges that are available for sale, leased, or placed at no charge with customers are charged to cost of sales. Depreciation expense for centrifuges used for sales and marketing and other internal purposes are charged to operations. When the centrifuges are sold the net book value is charged to cost of sales.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Management reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible Assets and Goodwill</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consist of definite-lived and indefinite-lived intangible assets, including goodwill.</div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Definite-lived intangible assets</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Our definite-lived intangible assets include trademarks, technology (including patents) and customer relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, we test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i. e., the asset is not recoverable), we would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. We periodically reevaluate the useful lives for these intangible assets to determine whether events and circumstances warrant a revision in their remaining useful lives. There were no triggering events identified during the three months ended March 31, 2014 that would suggest an impairment test may be needed.</div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Indefinite-lived intangible assets</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We evaluate our indefinite-lived intangible asset, consisting solely of in-process research and development (“IPR&D”) acquired in the Aldagen acquisition, for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis on October 1 of each year, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, we would recognize an impairment loss in the amount of that excess. There were no triggering events identified during the three months ended March 31, 2014 that would suggest an impairment test may be needed (Note 11).</div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Goodwill</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Amounts allocated to goodwill are tax deductible in all relevant jurisdictions. As a result of our acquisition of Aldagen in February 2012, we recorded goodwill of approximately $422,000. Prior to the acquisition of Aldagen, we had goodwill of approximately $707,000 as a result of the acquisition of the Angel business in April 2010.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value (Note 11).</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Conditionally Redeemable Common Stock</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The Maryland Venture Fund (“MVF,” part of Maryland Department of Business and Economic Development) has an investment in our common stock, and can require us to repurchase the common stock, at MVF’s option, upon certain events outside of our control; provided, however, that in the event that, at the time of either such event our securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. MVF’s common stock is are classified as “contingently redeemable common shares” in the accompanying condensed consolidated balance sheets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We recognize revenue when the four basic criteria for recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.</div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Sales of products</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We provide for the sale of its products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not maintain a reserve for returned products as in the past those returns have not been material.</div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Usage or leasing of blood separation equipment</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">As a result of the acquisition of the Angel® business in 2010, we acquired various multiple element revenue arrangements that combine the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. Under these arrangements, the total arrangement consideration is allocated to the various elements based on their relative estimated selling prices. The usage of the blood separation processing equipment is accounted for as an operating lease; since customer payments are contingent upon the customer ordering new products, rental income is recorded following the contingent rental method when rental income is earned and collectability is reasonably assured. The sale of disposable processing sets and supplies and maintenance are deemed a combined unit of accounting; since (a) any consideration for disposable processing sets and supplies and maintenance is contingent upon the customer ordering additional disposable processing sets and supplies and (b) both the disposable products and maintenance services are provided over the same term, we recognize revenue for this combined unit of accounting following the contingent revenue method at the time disposable products are delivered based on prices contained in the agreement. Rental income is currently less than 10% of total revenue and we therefore do not make separate disclosure in the statement of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as “Royalties” in the consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Deferred revenue at March 31, 2014 consists of prepaid licensing revenue of $1,743,635 and deferred sales of $67,632 from the prepayment of Angel centrifuges. Revenue of $100,594 related to the prepaid license was recognized during the three months ended March 31, 2014. On January 1, 2013 a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices. We report the medical device excise tax on a gross basis, recognizing the tax as both revenue and costs of sales.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Segments and Geographic Information</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We operate in one business segment. Product sales by geographic area consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <table style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: -24pt 0pt 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; FONT-FAMILY: Times New Roman, Times, Serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: normal; PADDING-TOP: 3pt" cellspacing="0" cellpadding="0" width="554"> <tr> <td></td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; WIDTH: 12px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td colspan="3"></td> <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; WIDTH: 12px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td colspan="3"></td> </tr> <tr> <td style="TEXT-ALIGN: left; LINE-HEIGHT: normal; FONT-SIZE: 8pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; LINE-HEIGHT: normal; FONT-SIZE: 8pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: bold" colspan="7"> <div>Three Months Ended March 31,</div> </td> </tr> <tr> <td style="TEXT-ALIGN: left; LINE-HEIGHT: normal; FONT-SIZE: 8pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: bold"> <div>  </div> </td> <td style="TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; LINE-HEIGHT: normal; FONT-SIZE: 8pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: bold" colspan="3"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; LINE-HEIGHT: normal; FONT-SIZE: 8pt; VERTICAL-ALIGN: text-bottom; FONT-WEIGHT: bold" colspan="3"> <div>2013</div> </td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; VERTICAL-ALIGN: text-bottom"> <div>Revenue from U.S. product sales</div> </td> <td style="TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div>$</div> </td> <td style="TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>1,030,122</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div>$</div> </td> <td style="TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>1,842,877</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204)"> <td style="BORDER-BOTTOM: white 1pt solid; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; VERTICAL-ALIGN: text-bottom"> <div>Revenue from non-U.S. product sales</div> </td> <td style="BORDER-BOTTOM: white 1pt solid; TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>393,096</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: white 1pt solid; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: white 1pt solid; TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>410,251</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: white 1pt solid; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="BORDER-BOTTOM: white 3pt double; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; VERTICAL-ALIGN: text-bottom"> <div>Total revenue from product sales</div> </td> <td style="BORDER-BOTTOM: white 3pt double; TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 3pt double; TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 3pt double; TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>1,423,218</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: white 3pt double; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: white 3pt double; TEXT-ALIGN: center; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> <td style="BORDER-BOTTOM: black 3pt double; TEXT-ALIGN: left; WIDTH: 6px; VERTICAL-ALIGN: text-bottom"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 3pt double; TEXT-ALIGN: right; VERTICAL-ALIGN: text-bottom"> <div>2,253,129</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: white 3pt double; TEXT-ALIGN: left; WHITE-SPACE: ; VERTICAL-ALIGN: text-bottom"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development Expenses</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Research and development costs are expensed as incurred and primarily consist of expenses relating to product development.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We have a stock-based compensation plan that includes stock options and other equity awards, which are awarded in exchange for employee, non-employee director and other non-employee services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Stock-based compensation cost for employee and non-employee director stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock is based on the closing market price of the stock at the grant date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period. Stock-based compensation for awards granted to non-employees is periodically remeasured as the underlying options and warrants vest. We recognize an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Valuation of stock awards requires management to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company’s stock price, dividend yields, future employee turnover rates, and future employee stock option exercise behaviors. Changes in these assumptions can affect the fair value estimate. We recognize the estimated fair value of stock-based awards and classify the expense where the underlying salaries or other related costs are classified.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Income tax expense was $4,645 and $4,890 during the three months ended March 31, 2014 and 2013, respectively relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our consolidated balance sheets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basic and Diluted Earnings (Loss) per Share</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding during the period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The total number of anti-dilutive shares, common stock options, warrants exercisable for common stock, convertible preferred stock and convertible debt, which have been excluded from the computation of diluted earnings (loss) per share, were 82,346,606 and 27,245,975 for the quarters ended March 31, 2014 and 2013, respectively.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our results of operations, financial position, or cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Convertible Debt ConvertibleDebt	75252	USD
CY2013Q4	us-gaap	Convertible Debt ConvertibleDebt	202658	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1341258	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1441852	USD
CY2014Q1	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.1	pure
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Trading Symbol TradingSymbol	CMXI
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	121700423	shares
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	CYTOMEDIX INC
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001091596
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	30000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82346606	shares
CY2014Q1	cmxi	Prepaid Licensing Revenue PrepaidLicensingRevenue	1743635	USD
CY2014Q1	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	67632	USD
CY2013Q1	cmxi	Medical Device Excise Tax Percentage MedicalDeviceExciseTaxPercentage	0.023	pure
CY2014Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	339000	USD
CY2013Q4	cmxi	Percentage In Number Of Shares PercentageInNumberOfShares	0.75	pure
CY2013Q4	cmxi	Exercise Price On Market Price ExercisePriceOnMarketPrice	1.25	pure
CY2013Q4	cmxi	Deferred Debt Issuance Cost DeferredDebtIssuanceCost	69000	USD
CY2014Q1	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	29600000	USD
CY2014Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	34958000	USD
CY2013Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	34958000	USD

Files In Submission

Name	View Source	Status
0001144204-14-031238-index-headers.html	Edgar Link	pending
0001144204-14-031238-index.html	Edgar Link	pending
0001144204-14-031238.txt	Edgar Link	pending
0001144204-14-031238-xbrl.zip	Edgar Link	pending
cmxi-20140331.xml	Edgar Link	completed
cmxi-20140331.xsd	Edgar Link	pending
cmxi-20140331_cal.xml	Edgar Link	unprocessable
cmxi-20140331_def.xml	Edgar Link	unprocessable
cmxi-20140331_lab.xml	Edgar Link	unprocessable
cmxi-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
line.gif	Edgar Link	pending
logo_cytomedix.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
spacer.gif	Edgar Link	pending
v377155_10q.htm	Edgar Link	pending
v377155_ex10-11.htm	Edgar Link	pending
v377155_ex31x1.htm	Edgar Link	pending
v377155_ex31x2.htm	Edgar Link	pending
v377155_ex32x1.htm	Edgar Link	pending
v377155_ex32x2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AURX
Nuo Therapeutics Inc Stock $aurx

2014 Q1 Form 10-Q Financial Statement

#000114420414031238 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX Nuo Therapeutics Inc Stock $aurx

2014 Q1 Form 10-Q Financial Statement

#000114420414031238 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX
Nuo Therapeutics Inc Stock $aurx